Brace Pharma
Venture capitalAtlanta · Late Stage · 3 people tracked
Find your way into Brace Pharma
2 people in our graph share verified history with the Brace Pharma team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Brace Pharma Capital invests in innovative therapies targeting diseases characterized by a high degree of unmet medical need and insufficient existing treatment options. The firm seeks to back companies developing life-changing medicines and invites prospective candidate investment companies to reach out for consideration.
Source: firm website, verified Aug 3, 2026.
Team · 3 people
from the firm's websiteWhat they invest in
from 13 of 15 portfolio companiesBiotech ×12Healthtech ×6Medical Devices ×4Deep Tech ×2Consumer ×1Digital Health ×1FemTech ×1Media & Entertainment ×1
HQs:United States×9
Investments · 15 tracked
founders shown can be your intro pathDiscovers and develops microRNA-targeting therapies for areas of high unmet medical need.
BiotechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Christopher J Morl(Executive Officer)Christopher Bowden(Director)Paul D. Rubin(Executive Officer)
Co-investorsMC Healthcare VenturesAtlas VentureBoulder VenturesRemeditex Ventures
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
DEREK JANTZ(Executive Officer, Director)inMATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
Co-investorsage1Aliment CapitalF-Prime CapitalOCV PartnersOUP (Osage University Partners)Pontifax AgTech+4 more
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsCTI Life Sciences Fund L.P.Lumira VenturesNextech InvestWUTIF Capital
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalCanaan PartnersLumira VenturesMPM BioImpactOUP (Osage University Partners)Sofinnova Ventures+3 more
BiotechLa Jolla, US
Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)Mark E. Davis(Director)Troy Wilson(Executive Officer, Director)
BoardTodd Brady(Director)Michael Martin PhD.(Director)
Co-investorsFrazier Life Sciences
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsF-Prime CapitalFrazier Life SciencesMoore Venture Partners
Co-investorsAisling Capital
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCSofinnova PartnersSunstone Capital+3 more
Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.
BiotechBaltimore, US
David S. Block(Executive Officer, Director)Elizabeth C. Block(Executive Officer)Raymond Shinazi(Director)Joseph Klein(Director)Mark Lerner(Director)
BoardCharles Polsky(Director)
Co-investorsFirst In Ventures
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)Marian Nakada(Director)Brian Gallagher(Director)in
Co-investorsage1Sanofi VenturesAtlas VenturePolaris PartnersSR One Capital Management
Reviral operates an affiliate review site that ranks and reviews online casinos not registered with the UK's GamStop self-exclusion scheme, comparing licences, bonuses, wagering terms, payout speeds, and payment methods.
ConsumerMedia & Entertainment
Co-investorsAndera PartnersNew Leaf Venture PartnersOrbiMedWellcome Trust
BiotechNew York, US
Michael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)Jane Henderson(Executive Officer)Stefan Larson(Director)Patrick Machado(Director)
Co-investorsF-Prime CapitalFACIT (Fight Against Cancer Innovation Trust)Foothill VenturesVenture OntarioOrbiMedPoint72+1 more
BiotechPalm Beach Gardens, US
Sheridan G. Snyder(Executive Officer, Director)Sheridan D. Snyder(Executive Officer)Michael Webb(Executive Officer, Director)Joseph Straight(Executive Officer)Chris Liang(Executive Officer, Director)
BoardTodd Brady(Director)
VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings.
BiotechHealthtechMedical Devices
Co-investorsRunway Growth CapitalMVM Life Science Partners
Exits · 3
IPOs and acquisitions across the tracked portfoliomiRagen TherapeuticsNASDAQ: VRDNPrecision BioSciencesNASDAQ: DTILZymeworksNASDAQ: ZYME
Portfolio news
latest coverage across their companies
Avidity Biosciences · fiercebiotech.com · Aug 11, 2026
Precision BioSciences · tradingkey.com · Aug 6, 2026
Zymeworks · finance.yahoo.com · Jul 1, 2026
F2G · endpoints.news · Jan 23, 2026
Frequently asked questions
- How many investments has Brace Pharma made?
- Brace Pharma has 15 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does Brace Pharma invest at?
- Brace Pharma invests at the Late Stage stage.
- What sectors does Brace Pharma focus on?
- Brace Pharma focuses on Biotech, Medical Devices.
- Where is Brace Pharma located?
- Brace Pharma is headquartered in Atlanta, US.
- Who does Brace Pharma co-invest with?
- Brace Pharma most often shares deals with F-Prime Capital, age1, Aisling Capital, among 34 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.